In a report released yesterday, Anthony Vendetti from Maxim Group maintained a Buy rating on Nephros Inc (NEPH), with a price target of $16.00. The company’s shares closed last Monday at $9.53, close to its 52-week high of $10.74.
According to TipRanks.com, Vendetti has 0 stars on 0-5 star ranking scale with an average return of -2.5% and a 40.8% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Ellex Medical Lasers Limited, Restoration Robotics Inc, and Ra Medical Systems Inc.
Nephros Inc has an analyst consensus of Moderate Buy, with a price target consensus of $16.00.
See today’s analyst top recommended stocks >>
Based on Nephros Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $1 million. In comparison, last year the company had a GAAP net loss of $550K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nephros, Inc. is a medical device company, which engages in developing and selling liquid purification filters and an on-line mid dilution hemodiafiltration system. The company operates in two segments: Water Filtration and Renal Products. The Water Filtration segments includes both the medical device and commercial filtration product lines.
